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ABSTRACT
Osteonecrosis of the jaws (ONJ) is a significant complication of antiresorptive medications, such as bisphosphonates and
denosumab. Antiresorptive discontinuation to promote healing of ONJ lesions remains highly controversial and understudied. Here,
we investigated whether antiresorptive discontinuation alters ONJ features in mice, employing the potent bisphosphonate
zoledronic acid (ZA) or the receptor activator of NF-kB ligand (RANKL) inhibitor OPG-Fc, utilizing previously published ONJ animal
models. Mice were treated with vehicle (veh), ZA, or OPG-Fc for 11 weeks to induce ONJ, and antiresorptives were discontinued for 6
or 10 weeks. Maxillae and mandibles were examined by mCT imaging and histologically. ONJ features in ZA and OPG-Fc groups
included periosteal bone deposition, empty osteocyte lacunae, osteonecrotic areas, and bone exposure, each of which substantially
resolved 10 weeks after discontinuing OPG-Fc but not ZA. Full recovery of tartrate-resistant acid phosphatase-positive (TRAPþ)
osteoclast numbers occurred after discontinuing OPG-Fc but not ZA. Our data provide the first experimental evidence
demonstrating that discontinuation of a RANKL inhibitor, but not a bisphosphonate, reverses features of osteonecrosis in mice. It
remains unclear whether antiresorptive discontinuation increases the risk of skeletal-related events in patients with bonemetastases
or fracture risk in osteoporosis patients, but these preclinical data may nonetheless help to inform discussions on the rationale for a
“drug holiday” in managing the ONJ patient. © 2015 American Society for Bone and Mineral Research.
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Introduction
Antiresorptive medications, such as bisphosphonates (BPs)and the receptor activator of NF-kB ligand (RANKL) inhibitor
denosumab impede osteoclastic bone resorption and are used
in the clinic to manage bone diseases, such as primary or
metastatic bone malignancy and osteoporosis. These medica-
tions, studied in cancer and postmenopausal women with
osteoporosis populations, reduce skeletal-related events (SREs),
decrease tumor burden, reduce bone pain, decrease incidence
of osteoporotic fractures, and help improve patients’ quality of
life.(1–4) Despite their distinctly different pharmacologic mecha-
nism of action, BPs and denosumab are each associated with
osteonecrosis of the jaw (ONJ), an infrequent but serious adverse
effect, particularly when administered at high doses.(5) Anti-
resorptive-related ONJ is defined as exposed bone or bone that
can be probed through an intraoral or extraoral fistula in the
maxillofacial region that has persisted for more than 8 weeks in
patients on current or previous treatment with antiresorptive
agents and no history of radiation therapy to the jaws or obvious
metastatic disease to the jaws.(6–8) The termmedical-related ONJ
(MRONJ) was recently introduced to include ONJ cases
associated with antiangiogenic therapies.(7)
Although ONJ has been described for more than a
decade,(9,10) the etiology and pathogenesis of the disease
remain largely unknown.(5,11–13) Osteoclast inhibition and bone
remodeling suppression, inflammation and/or infection, inhibi-
tion of angiogenesis, soft tissue toxicity, and altered immune cell
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function are among the hypotheses proposed to underlie ONJ
development and progression.(5,11–13) Clinical observations and
experimental findings provide support for several of these
hypotheses, suggesting that ONJ is probably a multifactorial
disease influenced by many variables.(7)
Because antiresorptive medications with distinct pharmaco-
logic function induce similar incidence of ONJ, osteoclastic
inhibition and bone turnover suppression appear central in
antiresorptive-related ONJ.(5,11–13) To that effect, discontinua-
tion of antiresorptive treatment before tooth extraction or other
dental surgical intervention or after ONJ development has been
proposed as potentially beneficial in improving osteoclast
function recovery, which could, in turn, increase bone turnover
and improve bone healing.(7,14–16) However, such recommen-
dations have only a theoretical basis, and clinical or experimen-
tal data supporting the benefit of antiresorptive drug
withdrawal in preventing ONJ development or promoting
resolution are lacking.(7,17) Furthermore, the consequences of
such “drug holidays” on the progression of SREs in cancer
patients or fragility fractures in osteoporosis patients remain
unclear. As such, an important first step in informing treatment
planning decisions is to understand whether discontinuation of
antiresorptive treatments mitigates the risk of developing ONJ
or fosters the resolution of established ONJ.(7,8)
Animal models recapitulating ONJ-like lesions in mice, rats,
minipigs, and dogs treated with bisphosphonates have provid-
ed important insights into ONJ pathophysiology.(18–29) More-
over, utilizing OPG-Fc and RANK-Fc as surrogates for
denosumab,(30) we reported for the first time ONJ-like lesions
in the presence of periapical disease or spontaneous perira-
dicular inflammation in mice treated with the RANKL inhib-
itors,(31,32) thus supporting the central role of osteoclastic
inhibition in ONJ pathogenesis. Similar ONJ-like changes were
reported more recently in mice that underwent tooth
extractions and were treated with an antibody against mouse
RANKL.(33)
In this study, utilizing ONJ animal models, we explored the
effects of zoledronic acid (ZA) or OPG-Fc discontinuation on
radiographic and histologic features of established ONJ in mice.
Our findings indicate that, within the experimental time frame,
OPG-Fc but not ZA discontinuation reversed features of
osteonecrosis in ONJ animal models.
Materials and Methods
Animal care
Mice and surgical procedures were handled according to the
guidelines of the Institutional Animal Care and Use Committee
of the University of California, Los Angeles. We followed a
randomized, prospective, controlled, animal model design
following all the recommendations of the ARRIVE (Animal
Research: Reporting In Vivo Experiments) guidelines for the
execution and submission of studies in animals (Kilkenny and
colleagues). Mice were kept in the animal facilities with
controlled temperature (23°C 2°C), humidity, and a 12-
hour light/dark cycle. Throughout the experimental period,
mice were housed in plastic cages, fed a standard laboratory
Fig. 1. Serum TRACP-5b levels increase after OPG-Fc but not after ZA discontinuation. TRACP-5b serum levels were measured at the end of treatment (0
weeks) and 2, 4, 6, and 10 weeks after drug discontinuation (13, 15, 17, and 21 weeks after the first injection) (n¼ 16/group per period). þStatistically
significantly different from indicated groups, p< 0.0001. **Statistically significantly different from indicated groups, p< 0.001. *Statistically significantly
different from indicated groups, p < 0.05.
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diet, and given water ad libitum. A total of 144 10-week-
old C57BL/6J wild-type male mice (Jackson Laboratories, Bar
Harbor, ME, USA) with average weight of 25 g were randomly
divided into three experimental groups of 48 animals that
received intraperitoneal (ip) injections of endotoxin-free saline
(group veh) two times per week, 10mg/kg rat OPG-
Fc (composed of the RANKL-binding domains of osteoprote-
gerin linked to the Fc portion of IgG,(32,34,35) kindly provided by
Amgen, Inc, Thousand Oaks, CA, USA) twice per week (group
OPG-Fc), or 200mg/kg zoledronic acid (Z-5744, LKT Laboratories,
St. Paul, MN, USA) twice per week (group ZA). These doses were
used to increase the incidence of ONJ-like lesions in the mice, as
described previously.
Periapical disease induction
Experimental periapical disease was performed as de-
scribed.(29,32,36,37) Briefly, the crowns of the right mandibular
1st and 2nd molars were drilled utilizing a stainless-steel 1/4 size
round bur in a high-speed handpiece, avoiding furcal perfora-
tion, and the root canals were left exposed to the oral
environment, resulting in pulpal necrosis and subsequent
Table 1. Summary of Radiographic and Histologic Findings on Various Groups and Experimental Time Points
Group Total no. of hemimandible and hemimaxillae Healthy (%) Diseased (%) Osteonecrosis (%) Bone exposure (%)
Veh 11w 64 34 (53)a 30 (47)a 0d (0)a (0)b 0f (0)a (0)b (0)þ
Veh 17w 64 31 (48)a 33 (52)a 2e (3.1)a (6)b 0d (0)a (0)b (0)c
Veh 21w 64 26 (40)a 38 (60)a 1e (1.5)a (2.6)b 0d (0)a (0)b (0)c
OPG-Fc 11w 64 32 (50)a 32 (50)a 24 (37.5)a (75)b 13 (20.3)a (40.6)b (54.2)c
OPG-Fc 17w 64 26 (40)a 38 (60)a 16g (25)a (42.1)b 3d (4.7)a (7.9)b (18.7)c
OPG-Fc 21w 64 24 (37)a 40 (63)a 13g (20.3)a (32.5)b 0d (0)a (0)b (0)c
ZA 11w 64 34 (53)a 30 (47)a 19 (29.7)a (63.4)b 10 (15.6)a (33.3)b (52.6)c
ZA 17w 64 27 (42)a 37 (58)a 32 (50)a (86.5)b 19 (29.7)a (51.4)b (59.3)c
ZA 21w 64 23 (36)a 41 (64)a 31 (48.4)a (75.6)b 21 (32.8)a (51.2)b (67.7)c
aPercent of total hemimaxillae and hemimandible.
bPercent of diseased hemimaxillae and hemimandible.
cPercent of hemimaxillae and hemimandible with osteonecrosis.
dStatistically significantly different, p < 0.05 compared with OPG-Fc and ZA.
eStatistically significantly different, p < 0.0001 compared with OPG-Fc and ZA.
fStatistically significantly different, p < 0.005 compared with OPG-Fc and ZA.
gStatistically significantly different, p < 0.0001 compared with ZA.
Fig. 2. Three-dimensionalmCT reconstructed images ofmaxilla. (A–C) Healthy site in veh, OPG-Fc, and ZA, respectively. (D, E) Diseased site after 11weeks
of treatment. (G–L) Diseased site at 6 and 10 weeks after drug discontinuation. Blue arrows point to normal alveolar bone crest in the interproximal area
between the distal root of the first molar and mesial root of the second molar. Red arrows point to periodontal bone loss and areas of osteolysis in the
diseased site of OPG-Fc- and veh-treated mice. Yellow arrows point to increased bone deposition.
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periapical infection. The crowns of the left 1st and 2nd molars
were kept intact.
Spontaneous naturally occurring maxillofacial abscesses
Naturally occurring, spontaneous maxillofacial abscesses
have been described in mice.(38) Hair inserts into the gingival
sulcus and results in bacterial colonization and reproducible,
severe periradicular osteolysis.(38–40) Such diseased maxillary
sites, identified by periradicular osteolysis by mCT imaging,
were compared with sites with healthy dento-
alveolar structures.(31)
Antiresorptive administration and serum TRACP-5b
measurement
Mice were pretreated with veh, OPG-Fc, or ZA for 3 weeks, and
periapical disease was induced. Animals continued to receive
veh, OPG-Fc, and ZA for 8 additional weeks, after which
antiresorptives were discontinued (Fig. 1A). Blood was collected
via retro-orbital bleeding after 11 weeks of the experiment (at
the end of antiresorptives treatment) and 2, 4, 6, and 10 weeks
after antiresorptive withdrawal. Serum tartrate-resistant acid
phosphatase 5b (TRACP-5b) was measured by enzyme immu-
noassay (RatTRAP; JDS, Gaithersburg, MD, USA).
Animal euthanization and analyses
Sixteen mice from each of the veh, OPG-Fc, and ZA groups were
euthanized via isoflurane overdose at 11 weeks (time of
antiresorptive discontinuation), at 17 weeks (6 weeks after
discontinuation), and at 21 weeks (10 weeks after antiresorptive
discontinuation). The maxillae, mandibles, and femurs were
fixed in 4% paraformaldehyde for 48 hours and stored in 70%
ethanol.
Micro-computed tomography (mCT) scanning
Maxillae and mandibles were imaged using a mCT scanner (mCT
Skyscan 1172; Skyscan, Kontich, Belgium) at 10mm resolution, as
described.(29,32) For linear measurements, axial slices were
converted to DICOM format and imported in the Dolphin
Fig. 3. mCT cross sections of the periapical area of first molars from animals treated with veh, OPG-Fc, and ZA followed by drug discontinuation. (A–C)
Nondrilledmolars at 11weeks. (D–F) Drilledmolars at 11weeks. (G–I) Drilledmolars 6weeks after drug discontinuation. (J–L) Drilledmolars 10weeks after
drug discontinuation (n¼ 16/group per period). Thin arrows point to normal PDL space. Arrowheads point to periapical bone loss. (M–O) Quantification
of periapical bone loss at the distal root of the first molar andmesial root of the secondmolar. #Statistically significantly different comparedwith all other
groups, p < 0.0001. þStatistically significantly different from indicated groups, p< 0.0001. **Statistically significantly different from indicated groups, p
< 0.001.
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Imaging software (Chatsworth, CA, USA). Periapical bone loss,
lamina dura thickness, periodontal ligament (PDL) space width,
lingual bone thickness, and cemento-enamel junction (CEJ) to
alveolar bone crest (ABC) distance were measured as de-
scribed.(29,31,32) Bone volume (BV), tissue volume (TV), and bone
volume fraction (BV/TV) of the alveolar weremeasured using the
CTAn software (Skyscan).
Femurs were imaged utilizing the mCT scanner at 12mm
resolution. Starting 100mm proximal to the distal growth plate,
200 axial slices were selected. BV, TV, BV/TV, trabecular number
(Tb.N), trabecular thickness (Tb.Th), and trabecular spacing (Tb.
Sp) were determined using the CTAn software. The measure-
ment terminology and units used for mCT analysis were those
recommended by the Nomenclature Committee of the Ameri-
can Society for Bone and Mineral Research.(41)
Histology and TRAP staining
Mandibles, maxillae, and femurs were decalcified in 14.5% EDTA
for 3 weeks and paraffin embedded, and 5mm sections were
obtained. Hematoxylin and eosin (H&E)-stained sections were
digitally scanned using the Aperio AT automated slide scanner
(Aperio Technologies, Inc, Vista, CA, USA). Using the ruler tool in
Aperio ImageScope software, the crestal 1mm of the alveolar
bone was marked and all measurements were performed in this
area for mandible and maxilla.
The epithelium to alveolar crest distance was measured in the
palatal side of themaxilla and in the lingual side of themandible.
The number of osteocytic lacunae and empty osteocytic lacunae
and the total bone area and osteonecrotic area (defined as five
or more contiguous empty osteocytic lacunae) were measured.
To quantify periosteal bone thickness, the Aperio ruler tool was
used tomeasure the three greatest areas of the buccal periosteal
thickness that were then averaged.
To quantify osteoclast number, sections of the mandible,
maxilla, and femur were stained using the leukocyte acid
phosphatase kit (Sigma-Aldrich, St. Louis, MO, USA) and TRAPþ
cells adjacent to the bone surface were counted. TRAPþ cells
were measured for 8 mice per group. All histology and digital
imaging were performed at the Translational Pathology Core
Laboratory (TPCL) at UCLA.
Statistics
Analyses were performed using GraphPad Prism Software (Graph-
Pad Software, Inc, La Jolla, CA, USA). Group measures were
expressed as mean the standard error of the mean (SEM).
Statistical significance was assessed using one-way analysis of
variance (ANOVA) followed by post hoc Tukey’s test for multiple
comparisons among groups. Data between groups (healthy versus
diseased) were compared using the Student’s t test. Categorical
data (Table 1) were analyzed using the Fisher’s exact test.
Fig. 4. SagittalmCT sections through the furcational periodontium of veh-, OPG-Fc-, and ZA-treated animals. (A–C) Nondrilled molars at 11 weeks. (D–F)
Drilledmolars at 11weeks. (G–I) Drilledmolars 6 weeks after drug discontinuation. (J–L) Drilledmolars 10weeks after drug discontinuation (n¼ 16/group
per period). Thin arrows point to lamina dura and arrowheads point to PDL space. (M–R) Quantification of changes in the furcational periodontium was
performed measuring the thickness of lamina dura and width of the PDL space. $Statistically significantly different compared with healthy mice,
p < 0.0001. &Statistically significantly different compared with diseased mice, p < 0.0001. þStatistically significantly different from indicated groups,
p < 0.0001. **Statistically significantly different from indicated groups, p < 0.001. *Statistically significantly different from indicated groups, p < 0.05.
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Results
Serum TRACP-5b levels increased after OPG-Fc but not
after ZA discontinuation
Serum TRACP-5b levels were measured at the end of
antiresorptive treatment (0 weeks: immediately after the last
injection and 11 weeks after the beginning of the experiment),
and 2, 4, 6, and 10 weeks after drug discontinuation (13, 15, 17,
and 21weeks after the beginning of the experiment). For the veh
group, serum TRACP-5b levels remained relatively steady with a
slight decline over time. After 11 weeks of treatment, ZA or OPG-
Fc significantly decreased serum TRACP-5b levels in all animals,
confirming the inhibition of osteoclastic function and absence of
neutralizing antibody production to OPG-Fc.(42) These TRACP-5b
levels remained unchanged for all groups 2 weeks after
antiresorptive discontinuation. Interestingly, by 4 to 6 weeks
post-OPG-Fc discontinuation, TRACP-5b rose above baseline
and then returned to baseline by 10 weeks. TRACP-5b post-
ZA discontinuation remained at reduced levels for 4 to 6 weeks
and progressively returned to baseline by 10 weeks (Fig. 1B).
OPG-Fc but not ZA discontinuation reversed
radiographic features of ONJ
The effect of antiresorptives and drug discontinuation on
maxilla, mandible, and femur was assessed by mCT. Healthy
maxillae in all groups showed normal alveolar crest extending
immediately below the cemento-enamel junction (CEJ), cover-
ing most of the root and the 1st and 2nd molar root furcation
and absence of bone resorption and/or bone expansion
(Fig. 2A–C; Supplemental Fig. S1A–C). In contrast, diseased
veh-treated mice showed altered alveolar bone morphology
with large loss of alveolar crest height; bone loss covering the
1st, 2nd, and 3rdmolars that in themajority of animals extended
almost to the root apex surrounding the entire root; and
significant buccal and palatal bone expansion of the alveolar
ridge. These changes were similar for all time points (Fig. 2D, G, J;
Supplemental Fig. S1D, G, J). In the diseased site of OPG-Fc- and
ZA-treated mice, bone loss was also present. However, the
extent of bone loss was significantly decreased and was
associated with large areas of periosteal bone apposition in
the buccal and palatal side of the maxillae that resulted in
substantial bone expansion (Fig. 2E, F; Supplemental Fig. S1E, F).
Discontinuation for 6 or 10 weeks of OPG-Fc but not ZA reversed
these effects, such that the OPG-Fc and veh groups appeared
similar and distinct from the ZA group (Fig. 2H, I, K, L;
Supplemental Fig. S1H, I, K, L). Similar findings were observed
for the mandibular alveolar ridge in nondrilled and drilled sites
of veh, OPG-Fc-, and ZA-treated animals (Supplemental Fig. S2).
We then quantified radiographic changes among the various
groups.(29,32) In the nondrilled side of all animals, a short apex to
bone distancewas observed (Fig. 3A–C). Significant distancewas
observed for the drilled site of veh animals at 11 weeks that
continued to increase over time (Fig. 3D, G, J, M, arrowheads). As
expected, OPG-Fc and ZA at 11 weeks reduced periapical bone
loss, reflected by shorter apex to bone distance (Fig. 3E, F, M).
Discontinuation of OPG-Fc reversed this effect, evidenced by a
significant increase of the apex to bone distance at 17 and
21 weeks (Fig. 3H, K, N, O, arrowheads). On the other hand, ZA
discontinuation had no effect in periapical bone loss (Fig. 3I, L, N,
O). Similar observations were found in maxillae with spontane-
ous periradicular bone loss. Both antiresorptive treatments
Fig. 5. Axial mCT sections through the maxillary alveolar ridge. (A–C) Healthy maxillae at 11 weeks. (D–F) Diseased maxillae at 11 weeks. (G–I) Diseased
maxillae 6 weeks after drug discontinuation. (J–L) Diseasedmaxillae 10 weeks after drug discontinuation (n¼ 16/group per period). Thin arrows point to
areas of osteolysis. Arrowheads point to bone deposition and bone expansion. (M–O) Quantification of buccal bone thickness. &Statistically significantly
different compared with diseased mice, p < 0.0001. þStatistically significantly different from indicated groups, p < 0.0001. **Statistically significantly
different from indicated groups, p < 0.001. *Statistically significantly different from indicated groups, p < 0.05.
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attenuated alveolar bone loss at 11 weeks. Six and 10 weeks of
OPG-Fc, but not ZA, discontinuation reversed the protection of
alveolar bone loss that was similar to veh-treated mice
(Supplemental Fig. S3).
Next, we examined changes of the PDL space width and
lamina dura thickness at the furcation area of the mandibular
molars.(29,32) In nondrilled teeth of veh-, OPG-Fc-, and ZA-
treated animals, a continuous PDL space and uniform lamina
dura that increased in thickness with antiresorptive treatment
were present (Fig. 4A–C, thin arrows and arrowheads). In the
drilled side of veh-treatedmice, there was increasedwidth of the
PDL space and loss of lamina dura that progressed over time
(Fig. 4D, G, J, thin arrows and arrowheads, and Fig. 4M, P). Both
antiresorptive treatments preserved PDL space width and
thickened lamina dura at 11 weeks (Fig. 4E, F, M–R). OPG-
Fc versus ZA discontinuation resulted in a significant reduction
in the thickness of lamina dura and increase in PDL space width
at 17 and 21 weeks (Fig. 4H, K, N, O, Q, R, thin arrows and
arrowheads). ZA discontinuation had no effect compared with
the week 11 measurements (Fig. 4I, L, N, O, Q, R).
The bone changes appeared to extend beyond the
confines of the periodontal area to the adjacent alveolar
bone (Fig. 5). Significant osteolysis with exuberant expansion
of the alveolar bone that increased over the time was noted
in the diseased versus healthy site of veh mice (Fig. 5A, D, G,
J, M–O, thin arrows). As previously reported,(29,32) antiresorp-
tive treatment inhibited bone osteolysis at 11 weeks (Fig. 5B,
C, E, F, M), with an associated exuberant bone deposition
on the buccal and palatal side of the alveolar ridge (Fig. 5B,
C, E, F, M, arrowheads). Importantly, 6 and 10 weeks of
OPG-Fc discontinuation reduced bone buccal and palatal
thickness to levels similar to the veh group (Fig. 5). In contrast,
ZA discontinuation had no effect on alveolar bone structure
compared with the prediscontinuation levels (Fig. 5H, I, K, L, N,
O). Similar findings were observed at the mandibular alveolar
ridge (Supplemental Fig. S4).
Periapical disease decreased BV and BV/TV compared with
the healthy site, and antiresorptives significantly increased BV
and BV/TV compared with the veh group at 11 weeks.
Significant increase in BV and BV/TV was observed between
diseased versus healthy sites in OPG-Fc and ZA mice (Fig. 6A,
B). OPG-Fc discontinuation decreased BV and BV/TV in the
drilled site that returned to values similar to the veh group
(Fig. 6C–F). In contrast, ZA discontinuation at 6 and 10 weeks
Fig. 6. Quantification of BV and BV/TV in the mandible of all mice. Eleven weeks of treatment (A, B) and 6 weeks (C, D) and 10 weeks (E, F) after drug
discontinuation (n¼ 16/group per period). $Statistically significantly different compared with healthy mice, p < 0.0001. &Statistically significantly
different compared with diseased mice, p < 0.0001. þStatistically significantly different from indicated groups, p < 0.0001. **Statistically significantly
different from indicated groups, p < 0.001. *Statistically significantly different from indicated groups, p < 0.05.
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had no effect on the BV and BV/TV levels (Fig. 6C–F). Similar
observations were made for the BV and BV/TV values of the
maxillae (Supplemental Fig. S5).
OPG-Fc but not ZA discontinuation reverses histologic
features of ONJ
As reported,(29,31,32) histologically healthy sites in all experi-
mental groups and time points showed normal marginal
epithelium (Fig. 7A–C; Fig. 8A–C, red arrows), PDL and
alveolar bone (Fig. 7A–C; Fig. 8A–C, turquoise arrows).
Abundant inflammatory infiltrate of the gingival and
connective tissue (Fig. 7D, G, J, black arrows), severe
destruction of the periradicular bone (Fig. 7D, G, J, turquoise
arrows), migration of the marginal epithelium (Fig. 7D, G, J,
red arrows), and bone expansion (Fig. 7D, G, J, blue arrows)
were observed in the diseased site of veh-treated animals at
all time points. Intense infiltration of inflammatory cells was
noted in the diseased site of OPG-Fc- and ZA-treated mice at
11 weeks of treatment (Fig. 7E, F; Fig. 8E, F, black arrows);
bone loss was present but appeared less compared with the
veh animals (Fig. 7E, F; Fig. 8E, F, turquoise arrows). Empty
osteocytic lacunae, areas of osteonecrosis (Fig. 7E, F; Fig. 8E,
F, yellow arrows), and abundant periosteal bone formation
(Fig. 7E, F; Fig. 8E, F, blue arrows) were found for both OPG-
Fc and ZA mice. In several animals, necrotic bone was not
covered by epithelium and was exposed to the oral cavity
(Fig. 7E, F; Fig. 8E–F, green arrows; Table 1).
After OPG-Fc discontinuation, extensive osteolysis was noted
in the maxillae, similar to the veh-treated animals (Fig. 7H, K;
Fig. 8H, K). Importantly, areas of osteonecrosis and bone
Fig. 7. Representative H&E-stained images frommaxilla of all groups. (A–C) Healthy site of veh, OPG-Fc, and ZA animals. (D–F) Diseased site at 11 weeks
at the end of antiresorptive treatment. (G–I) Diseased site of veh, OPG-Fc, and ZA 6 weeks after antiresorptive discontinuation. (J–L) Diseased site of veh,
OPG-Fc, and ZA 10 weeks after antiresorptive discontinuation. Red arrows point tomarginal gingival epithelium, turquoise arrows to alveolar crest, black
arrows to areas of inflammation, blue arrows to periosteal bone deposition, yellow arrows to osteonecrotic areas, and green arrows to areas of bone
exposure. Original magnification 5.
Fig. 8. Histologic appearance of periodontal and alveolar crest area of
maxillae (A–C) Healthy site of veh, OPG-Fc, and ZA animals. (D–F)
Diseased site at 11 weeks at the end of antiresorptive treatment. (G–I)
Diseased site of veh, OPG-Fc, and ZA 6 weeks after antiresorptive
discontinuation. (J–L) Diseased site of veh, OPG-Fc, and ZA 10 weeks
after antiresorptive discontinuation. Turquoise arrows point to alveolar
crest, black arrows to areas of inflammation, blue arrows to periosteal
bone deposition, yellow arrows to osteonecrotic areas, and green arrows
to areas of bone exposure. Original magnification 10.
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exposed to the oral cavity significantly decreased by 6 weeks
and were almost completely absent by 10 weeks of OPG-
Fc discontinuation. Significant bone resorption and decreased
areas of necrosis were associated with epithelial migration to
areas of vital bone and with decreased number of animals with
bone exposure (Fig. 7H, K; Fig. 8H, K; Table 1). In contrast, 6 and
10 weeks after ZA discontinuation did not alter these histologic
features (Fig. 7I, L; Fig. 8I, L). Similar observations were made for
healthy and drilled sites of the mandible for all experimental
groups (Supplemental Fig. S6A–L).
In maxillae, increased marginal epithelium to alveolar bone
crest (ABC) distance for diseased sites of veh animals at 11 weeks
that continued to increase over time was found. As
reported,(29,31,32) antiresorptive treatment significantly de-
creased this distance because of reduced bone resorption
(Fig. 9A–C). After OPG-Fc discontinuation, the epithelium to ABC
distance progressively increased, as a result of increased bone
resorption, and was statistically different compared with healthy
sites or ZA-treated diseased sites (Fig. 9B). Six weeks after ZA
discontinuation, the epithelium to ABC distance remained low
and significantly different from the other groups (Fig. 9B). At
10 weeks after ZA discontinuation, an increase in the epithelium
to ABC distance was noted but remained statistically different
compared with the other groups (Fig. 9C). Similar results were
found for the nondrilled and drilled sites of the mandible
(Supplemental Fig. S7A–C). A significant increase in periosteal
thickness was noted in the diseased versus healthy side for all
treatment groups at all experimental time points. No consistent
effects were noted by antiresorptive treatment or drug
discontinuation (Fig. 9A–C).
The number of empty osteocytic lacunae (Fig. 9G–I) and
osteonecrotic surface area (Fig. 9J–L) were measured in the
maxilla. No statistically significant presence of empty osteo-
cytic lacunae was detected in healthy or diseased sites of veh
mice or healthy sites of OPG-Fc or ZA mice at any time point.
As previously reported,(29,31,32) significant increases in empty
osteocytic lacunae (Fig. 9G–I) and osteonecrotic area (Fig. 9J–L)
were present in the diseased sites of mice on antiresorptive
treatment at 11 weeks. Six and 10 weeks after OPG-
Fc discontinuation, a significant reduction of empty osteocytic
lacunae and osteonecrotic area was noted, to levels statisti-
cally similar to those of healthy sites and significantly lower
than the diseased site of the ZA group. Interestingly, at 6 and
10 weeks after ZA discontinuation, significant increases in
empty osteocytic lacunae number and osteonecrotic areas
were observed. Comparable findings were observed for
nondrilled and drilled sites of the mandible (Supplemental
Fig. S7D–I).
Few TRAPþ cells were found at the healthy site of veh
animals but were significantly increased at the diseased site of
veh animals at all time points (Fig. 10A, D). TRAPþ cells
were absent in OPG-Fc-treated animals in both healthy and
diseased sites at 11 weeks (Fig. 10B, E, M). As previously
reported,(29,31,32) at 11 weeks TRAPþ cells in the diseased sites
of ZA mice increased but demonstrated round morphology,
with pyknotic nuclei, and were detached from the bone
surface (Fig. 10C, F, M). After OPG-Fc discontinuation, TRAPþ
cells in the diseased sites increased to higher levels than all
other groups at 17 weeks and higher than the healthy sites of
OPG-Fc animals at 21 weeks (Fig. 10H, K, N, O). A slight
significant increase in TRAPþ cell number was found in the
diseased sites after ZA discontinuation. Similar results
were found for the nondrilled and drilled sites of the mandible
(Supplemental Fig. S8A–O).
Fig. 9. Quantification of histologic findings. (A–C) The shortest epithelial-crest distance was determined. (D–F) Thickness of periosteum at the buccal
side was measured. (G–I) Osteocytic lacunae were measured and empty lacunae were expressed as percent of total. (J–L) Area of osteonecrosis was
measured and expressed as percent of total bone area (n¼ 16/group per period). þStatistically significantly different from indicated groups, p< 0.0001.
**Statistically significantly different from indicated groups, p < 0.001. *Statistically significantly different from indicated groups, p < 0.05.
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Table 1 summarizes radiographic and histologic findings.
Disease prevalence, which included periradicular and periapical
disease, ranged from 47% to 64%, with no statistical differences
among treatment groups or time points. Small areas of
osteonecrosis were found in 2 veh-treated mice at 17 weeks
and 1 at 21 weeks. Osteonecrosis was present in 75% of OPG-
Fc and 63.4% of ZA animals at 11 weeks with no difference
between antiresorptive groups but statistically different com-
pared with veh. Bone exposure was observed only in animals on
antiresorptives, ranging from 40.6% of the OPG-Fc and 52.6% of
ZA-treated mice, respectively. After OPG-Fc discontinuation,
areas of osteonecrosis and bone exposure were markedly
diminished. Osteonecrosis incidence decreased to 42.1% and to
32.5% at 6 and 10 weeks after OPG-Fc discontinuation,
respectively. Bone exposure decreased to 7.9% at 6 weeks after
discontinuation. Importantly, at 10 weeks after OPG-
Fc discontinuation, no animal with bone exposure was found.
In contrast, 6 and 10 weeks of discontinuation in ZA-
treated mice had no effect on incidence of osteonecrosis or
bone exposure compared with prediscontinuation levels at
11 weeks.
To assess effects of antiresorptive discontinuation in other
bones, we investigated radiographic changes in the femur of all
groups and time points. As expected, after 11 weeks of
treatment, antiresorptives caused an increase in all bone
radiographic indices including BV, BV/TV, trabecular number,
and trabecular thickness. OPG-Fc induced a slightly higher
trabecular thickness and smaller trabecular number compared
with ZA. OPG-Fc discontinuation resulted in a progressive
decrease in all measurements to veh levels. However, ZA
discontinuation showed little effect and all radiographic indices
remained high at both the 17- and 21-week time points
(Fig. 11A–M).
To explore the effects of various treatments on osteoclast
inhibition in femurs, TRAPþ cells were measured in the proximal
femur. The number of TRAPþ cells in veh mice did not change
over time (Fig. 11N, Q, T). At 11 weeks, no TRAPþ cells were
observed in OPG-Fc mice (Fig. 11O), whereas increased TRAPþ
cell numbers were found in ZA mice. However, in ZA mice, the
osteoclasts had a round shape and were detached from the
bone surface (Fig. 11P), with similar morphologic features as
observed in the maxilla (Fig. 10) and mandible (Supplemental
Fig. S8). At 6 and 10 weeks after OPG-Fc discontinuation, the
number of TRAPþ cells significantly increased compared with
the veh group (Fig. 11R, U, W). ZA discontinuation had no effect
on TRAPþ cell numbers.
Fig. 10. Representative sections of the maxilla stained for TRAPþ cells (original magnification5). Insets are magnified views of individual TRAPþ cells
(originalmagnification20). (A–C) Healthy site of veh, OPG-Fc, and ZA animals. (D–F) Diseased site at 11weeks at the end of antiresorptive treatment. (G–
I) Diseased site of veh, OPG-Fc, and ZA 6 weeks after antiresorptive discontinuation. (J–L) Diseased site of veh, OPG-Fc, and ZA 10 weeks after
antiresorptive discontinuation. (M–O) Quantification of TRAPþ cell number (n¼ 8/group per period). þStatistically significantly different from indicated
groups, p< 0.0001. **Statistically significantly different from indicated groups, p < 0.001. *Statistically significantly different from indicated groups, p <
0.05.
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Discussion
BPs are antiresorptive agents widely used in bone diseases with
elevated osteoclastic activity, such as osteoporosis, cancer
metastases to bone, multiple myeloma, and hypercalcemia of
malignancy. Recently, the US FDA approved denosumab, an
anti-RANKLmonoclonal antibody, for the prevention of skeletal-
related events in patients with bone metastases from solid
tumors, for the management of unresectable giant cell tumors,
for increasing bone mass in nonmetastatic prostate patients
with androgen deprivation therapy, breast cancer patients
receiving adjuvant aromatase inhibitor therapy, and men with
osteoporosis, and for the treatment of postmenopausal and
male osteoporosis.(43–45) Although both BPs and denosumab
target the osteoclast, their mechanism of function is distinctly
different.
BPs have high affinity to bone surfaces, where they remain
inactive until they are released during osteoclastic bone resorp-
tion.(46–50) Because they target bones with high turnover, BP
skeletal distribution is not homogeneous. The availability of
exposed hydroxyapatite, blood supply, and the ratio of bone
surface to bone volume are parameters thatmay contribute to this
uneven distribution.(51) On the other hand, denosumab, a high-
affinity, highly specific monoclonal antibody for human RANKL,
inhibits osteoclastic formation, function, and survival.(52,53) Upon
subcutaneous injection, denosumab is absorbed via the lymphatic
system, with subsequent drainage into the vasculature. Three
phases of drug distribution are described: a prolonged absorption
phase with maximum serum concentration at 5 to 21 days, a long
duration phase with a 32-day maximum half-life, and a rapid
terminal phase when serum concentrations reach levels below
1000ng/mL.(54,55)
Given their distinct biodistribution and mechanism of action,
BP versus denosumab inhibition of osteoclastic function has
distinct temporal dynamics. Because of their incorporation in
the bone mineral, BPs can exert their anti-osteoclastic effects
long after their administration.(46) In contrast, denosumab does
not require binding to bone mineral to exert its anti-
osteoclastic activity(30) and demonstrates rapid reversibility of
its antiresorptive effects.(43)
Here, we investigated osteoclast recovery by measuring
serum TRACP-5b levels before and at various times after
antiresorptive discontinuation. As expected, ZA treatment
significantly attenuated TRACP-5b levels. After ZA discontinua-
tion, TRACP-5b levels gradually returned to baseline, remaining
lower than the veh group for up to 6 weeks and reaching veh
group levels by 10 weeks after drug withdrawal. These findings
resemble data from the FLEX randomized trial showing that in
osteoporotic patients receiving alendronate for 5 years, BP
discontinuation results in a gradual increase of serum bone
resorption and formation markers measured at 3 and 5 years
after discontinuation.(56) A faster recovery of bone turnover
markers is reported at 1 year after BP discontinuation in
osteoporotic patients receiving risedronate for 3 years.(57) The
HORIZON-Pivotal Fracture Trial (PFT) reported that annual ZA
infusions are efficacious in decreasing bone turnover and
reducing fracture risk in postmenopausal women with osteopo-
rosis.(58) Interestingly, in the HORIZON extension, discontinua-
tion of iv ZA infusions for a period of 36 months showed that
bone turnover markers increase only slightly compared with
controls continuing to receive ZA.(59) These variations in
resolution of bone turnover indices after BP discontinuation
could reflect differences in BP biodistribution, bone mineral
affinity, and mode of administration.
Fig. 11. Representative sagittal mCT slices of femurs. (A–I) Veh, OPG-Fc, and ZA at the end of treatment and after drug discontinuation. (J–M)
Quantification of BV, BV/TV, Tb.N, and Tb.Th (n¼ 16/group per period). Representative sections of TRAP-stained sections from femurs (original
magnification5). Insets aremagnified views of individual TRAPþ cells (original magnification20). (N–P) Veh, OPG-Fc, and ZA animals at 11 weeks, (Q–
S) 6 weeks after drug discontinuation, and (T–V) 10 weeks after drug discontinuation. (W) Quantification of TRAPþ cell number (n¼ 8/group per period).
&Statistically significantly different compared with diseased mice, p < 0.0001. þStatistically significantly different from indicated groups, p < 0.0001.
**Statistically significantly different from indicated groups, p < 0.001. *Statistically significantly different from indicated groups, p < 0.05.
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The RANKL inhibitor OPG-Fc was used as a surrogate to
denosumab because the latter does not recognize the mouse
RANKL.(30) OPG-Fc treatment significantly reduced serum
TRACP-5b levels that declined to levels lower than veh- or ZA-
treated animals. Interestingly, at 4 and 6 weeks after OPG-
Fc discontinuation, TRACP-5b levels rose above those in the veh-
treated group and declined to baseline by 10 weeks. These
results parallel observations from studies in postmenopausal
patients with osteoporosis, wherein denosumab discontinua-
tion led to recovery of bone resorption markers that transiently
exceeded pretreatment levels before recovering to normal.(60)
At the tissue level, denosumab treatment reduces bone
turnover, including eroded surfaces and tetracycline label-
ing.(61,62) After denosumab cessation, bone histomorphometry
indices return to pretreatment levels, indicating that the effects
of denosumab on bone turnover are fully reversible.(63)
Given the great importance of osteoclasts in bone healing and
in periapical and periodontal disease progression(64–67) and the
central role of bone remodeling suppression in ONJ pathophys-
iology,(5,11,12) discontinuation of oral bisphosphonates in
patients with low bone turnover marker values was recom-
mended to allow recovery of osteoclastic function before dental
surgical procedures.(68) However, such recommendations have
been questioned, and the significance of oral bisphosphonate
discontinuation in the management of the ONJ patient remains
controversial.(69)
Recommendations for discontinuation of antiresorptive medi-
cation by professional organizations are cautious and based on
theoretical assumptions. For osteoporotic patients, the American
Dental Association (ADA) Council on Scientific Affairs recommends
that before a dental procedure, “discontinuation of antiresorptive
therapy should be amedical decision based primarily on the risk of
experiencing SRE secondary to low bone density, not the potential
risk of developing ARONJ.”(15) The AAOMS position paper reports
that a theoretical benefit might exist for patients with history of
prolonged bisphosphonate treatment (>4 years),(7) whereas the
International Task Force opines that “it may be advisable to stop
antiresorptive therapy if it is possible to do so without adverse
consequences for bone health.”(8) Similarly, recommendations for
patients receiving oncologic doses of antiresorptives on drug
discontinuationbefore surgical dental procedures are inconclusive.
For patients who have developed ONJ, discontinuation of
antiresorptive medication until closure of the soft tissue defect
with well-epithelializedmucosamay be considered, depending on
the systemic disease status. A potentially greater rate of ONJ
resolution upon discontinuation of denosumab (40.4%) versus ZA
(29.7%) in cancer patients with bone metastases has been
reported.(70) However, the benefit of such drug discontinuation
in ONJ healing is unclear. All reports uniformly describe the lack of
evidence to support or contradict utilization of drug withdrawal in
themanagement of patients on antiresorptives and emphasize the
great importance of studies that would inform such clinical
decisions.(7,8,70)
To address this void in our understanding of ONJ manage-
ment as it pertains to drug holidays for resolution of existingONJ
lesions, we treated mice with high-dose OPG-Fc to inhibit
RANKL-RANK signaling or with ZA to develop ONJ lesions and
then discontinued drug administration for 6 or 10 weeks.
Qualitative and quantitative radiographic and histologic analysis
of mandibles and maxillae revealed that both antiresorptive
treatments successfully induced ONJ-like lesions in mice, similar
to our previous observations.(29,31,32) Upon discontinuation of
OPG-Fc, radiographic indices of alveolar bone loss, such as PDL
space width, lamina dura loss, and alveolar BV and BV/TV, were
similar to the veh-treated animals. However, ZA cessation did
not significantly alter radiographic appearance within the
experimental time frame. Importantly, OPG-Fc discontinuation
progressively decreased histologic features of ONJ, including
number of empty osteocytic lacunae, osteonecrotic area, and
presence of exposed bone. In contrast, for both time points of
ZA, all histologic indices of ONJ remained similar to the
prewithdrawal levels and different than both the veh and OPG-
Fc groups. An interesting caveat that our studies did not address
is whether ONJ incidence and severity would have progressed if
antiresorptives were continuously present for the 21 weeks of
the experiment. Thus, although it remained the same pre- and
post-ZA withdrawal, ONJ burden could have potentially
worsened if ZA were continuously present. If that were true,
ZA withdrawal would have ablated this increased burden.
The reversal of ONJ radiographic and histologic findings after
OPG-Fc discontinuation was paralleled by a robust recovery of
osteoclastic function, indicated by the increased serum TRACP-
5b levels and the increased osteoclast numbers in the femur and
the diseased sites of the mandible and maxillae. Because OPG-
Fc withdrawal was associated with bone loss that progressively
reached similar levels to that of veh animals and with increased
osteoclast numbers and activity, the reduction in osteonecrotic
areas appears to be mainly attributable to removal of the
necrotic bone by the recovered osteoclasts. Increased bone
remodeling, although probably present in areas of inflamma-
tion, appeared less likely to play a significant role in the reduced
bone necrosis and exposure.
The close association of osteoclastic recovery to ONJ burden
points to the central involvement of osteoclastic function, not
only for ONJ pathogenesis but also, importantly, for ONJ
resolution. Our data collectively demonstrate that OPG-Fc, but
not ZA, discontinuation reversed radiographic and histologic
features of osteonecrosis and support theoretical predictions
based on antiresorptive pharmacokinetics and mode of action
hypothesizing that denosumab withdrawal leads to higher
recovery rates of ONJ compared with ZA because of denosu-
mab’s reversible inhibition of osteoclastic activity.(70,71) Al-
though our findings are potentially instructive for other settings
of drug holidays, such as before tooth extractions or oral surgical
interventions, future studies that directly address these
scenarios would provide valuable insight into usefulness of
antiresorptive withdrawal to prevent ONJ development.
In conclusion, we report that antiresorptive treatment discon-
tinuation alters radiographic and histologic findings of ONJ inmice
differently, depending on the type of antiresorptive agent. To the
best of our knowledge, this is the first experimental study to
illustrate and quantify such differences. Our findings provide a
rationale that informs clinical decisions for drug holidays in the
management of the ONJ patient. Indeed, if our findings remain
translatable to the clinical setting, they would suggest that for
patients receiving high-dose antiresorptives for the management
of malignancy, denosumab discontinuation would offer faster and
more complete resolution of ONJ compared with BPs.
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